221 results on '"Isabelle Plo"'
Search Results
2. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms
3. The double-edged sword of adenosine
4. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model
5. ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis
6. Lyl-1 regulates primitive macrophages and microglia development
7. Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN
8. Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms
9. HSPCs display within-family homogeneity in differentiation and proliferation despite population heterogeneity
10. Identification of biallelic germline variants of SRP68 in a sporadic case with severe congenital neutropenia
11. TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells
12. Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis
13. HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis
14. Altered Ca2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis
15. Critical role of the HDAC6–cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect
16. MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors
17. New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis
18. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders [version 1; referees: 2 approved]
19. p19INK4d Controls Hematopoietic Stem Cells in a Cell-Autonomous Manner during Genotoxic Stress and through the Microenvironment during Aging
20. Identification of MPL R102P Mutation in Hereditary Thrombocytosis
21. Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis
22. Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint
23. Eltrombopag, a potent stimulator of megakaryopoiesis
24. Recent advances in understanding myelofibrosis and essential thrombocythemia [version 1; referees: 2 approved]
25. Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients.
26. Isolation of Human Blood Progenitor and Stem Cells from Peripheral Blood by Magnetic Bead
27. Protein Translation Study – Label Protein with S35 Methionine in Cells
28. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
29. Supplementary Data from In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
30. Data from In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
31. Supplementary Table from In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target
32. Data from Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status
33. Supplementary Data from Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status
34. Oral SGLT2 Inhibitors in Glycogen Storage Disease Type Ib and G6PC3-Deficiency. Preliminary Results from an Off-Label Study of 21 Patients
35. Supplementary Figure 1 from AKT1 Inhibits Homologous Recombination by Inducing Cytoplasmic Retention of BRCA1 and RAD51
36. Supplementary Figure Legends from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
37. Supplementary Figure 5 from AKT1 Inhibits Homologous Recombination by Inducing Cytoplasmic Retention of BRCA1 and RAD51
38. Supplementary Figure 6 from AKT1 Inhibits Homologous Recombination by Inducing Cytoplasmic Retention of BRCA1 and RAD51
39. Supplementary Figure 4 from AKT1 Inhibits Homologous Recombination by Inducing Cytoplasmic Retention of BRCA1 and RAD51
40. Supplementary Methods from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
41. Supplementary Figure 2 from AKT1 Inhibits Homologous Recombination by Inducing Cytoplasmic Retention of BRCA1 and RAD51
42. Supplementary Figure 3 from AKT1 Inhibits Homologous Recombination by Inducing Cytoplasmic Retention of BRCA1 and RAD51
43. Supplementary Movie from AKT1 Inhibits Homologous Recombination by Inducing Cytoplasmic Retention of BRCA1 and RAD51
44. Supplementary Figures 1 - 5 from Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells
45. Inferring the initiation and development of myeloproliferative neoplasms
46. An inherited gain‐of‐function risk allele in <scp> EPOR </scp> predisposes to familial <scp> JAK2 V617F </scp> myeloproliferative neoplasms
47. ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis
48. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms
49. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model
50. PI3K Signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.